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Molecular imaging of tauopathies is complicated by the differing specificities and off-
target binding properties of available radioligands for positron emission tomography
(PET). [18F]-APN-1607 ([18F]-PM-PBB3) is a newly developed PET tracer with promising
properties for tau imaging. We aimed to characterize the cerebral binding of [18F]-APN-
1607 in Alzheimer’s disease (AD) patients compared to normal control (NC) subjects.
Therefore, we obtained static late frame PET recordings with [18F]-APN-1607 and [18F]-
FDG in patients with a clinical diagnosis of AD group, along with an age-matched NC
group ([18F]-APN-1607 only). Using statistical parametric mapping (SPM) and volume
of interest (VOI) analyses of the reference region normalized standardized uptake value
ratio maps, we then tested for group differences and relationships between both PET
biomarkers, as well as their associations with clinical general cognition. In the AD group,
[18F]-APN-1607 binding was elevated in widespread cortical regions (P < 0.001 for VOI
analysis, familywise error-corrected P < 0.01 for SPM analysis). The regional uptake
in AD patients correlated negatively with Mini-Mental State Examination score (frontal
lobe: R = -0.632, P = 0.004; temporal lobe: R = -0.593, P = 0.008; parietal lobe: R = -
0.552, P = 0.014; insula: R = -0.650, P = 0.003; cingulum: R = -0.665, P = 0.002)
except occipital lobe (R = -0.417, P = 0.076). The hypometabolism to [18F]-FDG PET
in AD patients also showed negative correlations with regional [18F]-APN-1607 binding
in some signature areas of AD (temporal lobe: R = -0.530, P = 0.020; parietal lobe:
R = -0.637, P = 0.003; occipital lobe: R = -0.567, P = 0.011). In conclusion, our
results suggested that [18F]-APN-1607 PET sensitively detected tau deposition in AD
and that individual tauopathy correlated with impaired cerebral glucose metabolism and
cognitive function.
Keywords: tau, neurodegeneration, metabolism, cognition, Alzheimer’s disease, positron emission tomography
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INTRODUCTION
The hyperphosphorylated, aggregated tau that comprises
intracellular filamentous inclusions is implicated in a number
of neurodegenerative pathologies (Spillantini and Goedert,
2013). In healthy adults, equal amounts of tau protein
isoforms with three microtubule-binding domains (3R)
and four microtubule-binding domains (4R) occur in the
cerebral cortex (Goedert and Jakes, 1990). Misassembly of
the normally unfolded microtubule-associated protein tau
into a highly structured amyloid fibril is implicated in the
pathological process underlying human tauopathies (Goedert
et al., 2017). Alzheimer’s disease (AD), which is primarily
associated with 3R and 4R tau (Rosler et al., 2019), is one of the
most clinically relevant tauopathies and is the most common
neurodegenerative disorder globally, bringing enormous burdens
to society and caregivers.
Consequently, molecular imaging of tauopathies has
garnered much interest in recent years, and there is increasing
recognition of tauopathy as a potential target in the early
detection of neurodegenerative disease or indeed as a potential
therapeutic target. Among available tracers for positron emission
tomography (PET), the selectivity for tau isoforms determines
their suitability for particular neurodegenerative disease. For
example, a head-to-head comparison of [11C]-THK5351 and
[11C]-PBB3 in AD patients revealed distinct binding patterns
for the two tracers in the same patients. [11C]-THK5351
binding matched the tau pathology expected for AD, whereas
[11C]-PBB3 binding showed a greater affiliation with β-amyloid
distribution (Chiotis et al., 2018). An immunofluorescence
study with PBB3 and AV-1451 both showed intense labeling of
non-ghost and ghost tangles, whereas detection of dystrophic
neurites in brain of AD patients was clearer for PBB3 (Ono
et al., 2017). Further quantitative autoradiographic analysis
post-mortem showed moderate [11C]-PBB3 autoradiographic
binding vs. relatively faint [18F]-AV-1451 labeling of the 3R
isoforms in brains of patients dying with Pick’s disease (PiD),
and likewise for the 4R isoforms in brains of patients dying
with progressive supranuclear palsy (PSP) or corticobasal
degeneration. However, the binding of the two ligands was
similar for paired helical filament (PHF)-tau in patients dying
with AD (Ono et al., 2017).
Off-target binding, at present one of the great challenges
in molecular neuroimaging of tauopathy, occurs then the
tracer has affinity to an unintended molecular target in the
brain. For example, the interpretation of tau burden in PET
scans with [18F]-THK5351 (Ng et al., 2017) and several other
ostensibly tau-selective tracers (Murugan et al., 2019) was
complicated by off-target binding to monoamine oxidase B
(MAO-B). Furthermore, the tau tracers [18F]-AV-1451, [18F]-
THK5351, and [18F]-MK6240 all showed additional binding
to neuromelanin (Aguero et al., 2019; Tago et al., 2019),
which likely accounted for their binding in the midbrain
dopamine neurons of the substantia nigra (Marquie et al., 2015;
Harada et al., 2016).
PBB3-based tracers show much promise in overcoming the
problem of incomplete specificity for tau. Previous studies
regarding the prototype [11C]-PBB3 revealed no cross-reactivity
with monoamine oxidase A (MAO-A) and MAO-B (Ni et al.,
2018), although there was a low affinity for non-tau fibrils
such as assemblages of amyloid-β (Maruyama et al., 2013; Ono
et al., 2017) and α-synuclein aggregates (Koga et al., 2017).
Nevertheless, [11C]-PBB3 binding was highly selective for tau
at the nm radioligand concentrations typically achieved in a
human PET study (Koga et al., 2017; Ni et al., 2018). However,
routine clinical use of the compound [11C]-PBB3 presented
logistic difficulties due to the short physical half-life of carbon-
11 (Hashimoto et al., 2014, 2015; Shimada et al., 2017). A PBB3
derivative labeled with longer-lived fluorine-18 might overcome
this limitation.
Moreover, according to the latest National Institute on
Aging – Alzheimer’s Association framework on AD (Jack
et al., 2018; Cummings, 2019), a framework comprising three
biomarkers β-amyloid (A), tau (T), and neurodegeneration
(N) is recommended for defining the AD spectrum and for
distinguishing AD from non-AD causes of cognitive impairment.
Detection of β-amyloid is accomplished with established PET
tracers such as [11C]-PiB (Klunk et al., 2004; Jimenez-
Bonilla et al., 2016) and [18F]-AV45 (Nemmi et al., 2014;
Brendel et al., 2015; Lin et al., 2016). These tracers show
progressive accumulation of β-amyloid first in isocortical areas
and later in limbic and cortical structures. Positron emission
tomography with [18F]-FDG reveals a characteristic pattern
of hypometabolism in temporoparietal cortex and posterior
cingulate of AD patients (Minoshima et al., 1995; Kato et al.,
2016; Hsu et al., 2017; Rice and Bisdas, 2017; Blazhenets et al.,
2019). Multimodal studies combining A/T/N biomarkers showed
tau deposition as measured by [18F]-AV-1451 (Sintini et al., 2019)
or [18F]-THK5351 (Baghel et al., 2019) PET, which correlated
with hypometabolism to [18F]-FDG PET and with atrophy,
as measured by structural magnetic resonance imaging (MRI)
(Sintini et al., 2019).
In this context, we presented [18F]-APN-1607 ([18F]-
PM-PBB3), a next-generation tau tracer derived from the
PBB3 series, but possessing a superior drug metabolism and
pharmacokinetic profile, improved specific binding in brain,
and the logistic advantage imparted by fluorine-18 (Shimada
et al., 2017, 2018; Tagai et al., 2020; see Supplementary
Table 1). We aimed in this study to characterize the
cerebral uptake pattern of [18F]-APN-1607 as a marker for
hyperphosphorylated tau in patients with clinically diagnosed
AD in comparison to a normal control (NC) group and
to investigate the correlation of this regional uptake with
hypometabolism to [18F]-FDG PET and in relation to impaired
cognitive function.
MATERIALS AND METHODS
Subjects
Nineteen clinically diagnosed and amyloid PET-positive AD
patients (6 underwent [11C]-PiB PET, and 13 underwent [18F]-
AV45 PET) and 11 NC subjects who also underwent [18F]-
APN-1607 PET in Huashan Hospital, Shanghai, China, were
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enrolled in this study from 2018/11 to 2019/11. All subjects
underwent anatomical MRI, and all AD patients underwent
an [18F]-FDG PET within 1 month before or after [18F]-
APN-1607 PET. The diagnosis of clinically probable AD was
based on current diagnostic criteria (McKhann et al., 2011).
Experienced radiologists assessed medial temporal lobe atrophy
(MTA) using MTA–Visual Rating Scale (VRS) blinded to clinical
conditions in all subjects. Experienced neurologists from the
cognitive impairment clinic administered the Mini-Mental State
Examination (MMSE) and Clinical Dementia Rating (CDR) test
for all patients. Meanwhile, the NC group also accepted CDR
test. None of the NCs had a history of cognitive impairment,
psychiatric illness, central nervous system disease, or head
injury. Furthermore, dementia caused by other reasons and
mild cognitive impairment (MCI) were excluded after clinical
screening by experienced neurologist/cognitive specialists. This
study was approved by the ethics committee of Huashan Hospital
(no. 2018-363). All procedures performed in this study were in
accordance with the ethical standards of the institutional research
committee and with the Helsinki Declaration of 1975 and its later
amendments. All subjects or a legally responsible relative gave
written informed consent before the study.
Imaging and Processing
Radiosynthesis
[18F]-APN-1607 was prepared in Huashan Hospital by a
nucleophic substitution reaction followed by an acid hydrolysis
carried out with an [18F]-multifunction synthesizer (Beijing PET
Technology Co., Ltd., Beijing, China). APRINOIA Therapeutics
(Suzhou, China) provided the tosylate precursor used for the
radiosynthesis. After purification with semipreparative high-
performance liquid chromatography, the product [18F]-APN-
1607 was formulated in ascorbate-containing normal saline
for injection and was filtered through a sterile membrane
filter. The radiosynthesis was completed in 90 min, giving
[18F]-APN-1607 with a radiochemical purity of ≥90% and a
molar activity of ≥37 MBq/µmol at the end of synthesis. The
production was conducted under the green light-emitting diode
light (510 nm) illumination, and the product was sterile and
negative for pyrogens.
Image Acquisition and Reconstruction
All subjects were scanned on a Siemens Biograph 64
PET/computed tomography (CT) (Siemens, Erlangen, Germany)
in three-dimensional (3D) mode in Huashan Hospital. A low-
dose CT transmission scan was performed before PET scanning
for attenuation correction. Static emission recordings were
acquired during the interval of 90–110 min after intravenous
injection of 370 MBq [18F]-APN-1607. Image reconstruction
was obtained by the ordered subset expectation maximization
3D (OSEM 3D) method. Patients with AD underwent [18F]-FDG
PET on another scanning day with intravenous injection of
185 MBq, following a scanning procedure and OSEM 3D
reconstruction as described in a previous study (Wu et al., 2013).
All subjects also underwent anatomical MRI in a 3.0-T horizontal
magnet (Discovery MR750; GE Medical Systems, Milwaukee,
WI, United States) at Huashan Hospital.
Semiquantitative Volume of Interest–Based PET
Analyses
The PNEURO data processing pipeline of PMOD version
4.005 (PMOD Technologies Ltd., Zurich, Switzerland) was used
for spatial normalization of all PET images to the Montreal
Neurological Institute (MNI) space, using the individual MRI
as an intermediate. Both [18F]-APN-1607 and [18F]-FDG PET
images were analyzed in the following manner: we first
segmented the individual MRI into gray matter (GM), white
matter (WM), and cerebrospinal fluid (CSF) and made the
spatial normalization to the MNI space. Subsequently, each
subject’s individual PET images were spatially matched to MRI
and then resampled using the normalization arising from the
GM/WM/CSF MRI segmentation procedure (Ashburner, 2007).
Based on the Atlas template [adult brain maximum probability
map (“Hammersmith atlas”; n30r83)], the whole brain was
parcellated into the following regions for standardized uptake
value ratio (SUVR) calculations: frontal, temporal, occipital, and
parietal lobes; insula; cingulum; caudate; putamen; pallidum;
thalamus; midbrain; pons; medulla; and cerebellar cortex. The
cerebellar cortex was selected as the reference region for tau
images because it has negligible tau pathology to examination
post-mortem AD cerebellum (Herrmann et al., 1999; Baghel
et al., 2019). The same reference region was used for [18F]-FDG
PET images (Leuzy et al., 2018; Baghel et al., 2019).
Voxel-Wise Analyses
Statistical parametric mapping (SPM) analysis was performed
using SPM8 (Wellcome Department of Cognitive Neurology,
London, United Kingdom) implemented in MATLAB 8.4
(R2014) (Mathworks Inc., Sherborn, MA, United States). The
[18F]-APN-1607 SUVR maps from the AD and NC groups were
compared by a voxel-wise two-tailed Student t-test after 10-
mm Gaussian smoothing. To evaluate significant differences,
we set the voxel threshold at P < 0.01 [familywise error
(FWE)-corrected] over the whole brain with an extent threshold
empirically chosen to be at least twice of the expected number of
voxels per cluster estimated in the SPM run. Significant regions
were localized by Talairach–Daemon software (Research Imaging
Center, University of Texas Health Science Center, San Antonio,
TX, United States). The SPM maps for abnormal [18F]-APN-
1607 uptakes were overlaid on a standard structural MRI brain
template in stereotaxic space. We then used multiple regression
analyses to determine the relationship between [18F]-APN-1607
uptake values and MMSE in the AD patients. Voxels surviving
P < 0.01 (uncorrected) with an extent threshold of at least twice
of the expected number of voxels per cluster estimated in the
SPM run were considered significant for the multiple regression
analyses. Moreover, clusters surviving at FWE P < 0.05 were also
searched for these multiple regression analyses.
Statistical Analysis
Demographic characteristics and semiquantitative PET results
in different target volumes of interest (VOIs) were compared
between AD and NC groups using the independent two-tailed
Student t-test, χ2 test, or Mann-Whitney U test as appropriate.
Effect sizes for the discrimination between patients and NC
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subjects were evaluated by Cohen d. Correlation analyses between
PET SUVR in target VOIs and clinical parameter (MMSE), as well
as intermodality correlations, were performed using Spearman
correlation. All statistical analyses were performed in SPSS
version 22.0 software (SPSS Inc., Chicago, IL, United States).
P < 0.05 was considered significant.
RESULTS
Demographic Information and Clinical
Characteristics
Our AD group consisted of 7 males and 12 females with mean age
61.8 (±11.3) years, whereas NC group included seven males and
four females with mean age 61.8years (±4.6) years. There were
14 early onset AD, who showed symptoms younger than 65 years
old and five late-onset AD (LOAD) in our cohort. Both groups
were comparable for age of scanning (P = 0.992) and gender
(P = 0.156). The general cognition of the AD group as assessed
by CDR-Global Score (CDR-GS) and MMSE score showed that
our patient cohort was mainly at moderate to advanced stages of
the disease (CDR-GS: 1 (1–2); MMSE: 17.0 ± 7.6). The MTA-
VRS showed that AD group had abnormal brain atrophy while
NC group showed normal (Table 1).
Semiquantitative VOI-Based PET
Analyses
Figure 1 shows the representative examples of [18F]-APN-
1607 PET and anatomical MRI superimposed images of AD
and NC subjects.
The AD group showed abnormally higher [18F]-APN-1607
binding than did the NC group in all cerebral lobes (P < 0.001,
Cohen d varying from 1.5 to 2.1), as well as in caudate (P < 0.05,
Cohen d = 0.9) and putamen (P < 0.001, Cohen d = 1.5).
Meanwhile, the AD group showed lower uptake of [18F]-APN-
1607 in midbrain (P < 0.01, Cohen d = 1.0), pons (P < 0.001,
Cohen d = 1.4), and medulla (P < 0.001, Cohen d = 1.5) (Table 2
and Figure 2).
As for clinical associations, [18F]-APN-1607 binding in all
cerebral lobes (with the exception of the occipital lobe) correlated
negatively with the MMSE score (frontal lobe: R = −0.632,
P = 0.004; temporal lobe: R = −0.593, P = 0.008; parietal lobe:
R = −0.552, P = 0.014; insula: R = −0.650, P = 0P = 0.003;
cingulum: R = −0.665, P = 0.002). Likewise, [18F]-APN-1607
binding in putamen, thalamus and medulla showed similar
correlations (putamen: R = −0.557, P = 0.013; thalamus:
R = −0.595, P = 0.007; medulla: R = −0.469, P = 0.043).
[18F]-FDG uptake, as a surrogate marker for neuronal metabolic
activity, showed positive correlations with MMSE in the frontal
and parietal lobes (frontal lobe: R = 0.469, P = 0.043, parietal
lobe: R = 0.550, P = 0.015). The temporal lobe also showed a
broadly similar correlation with MMSE, albeit without reaching
significance (R = 0.444, P = 0.057) (Table 3).
We then interrogated the relationships between [18F]-APN-
1607 and [18F]-FDG. We found negative correlations between
tau deposition and FDG uptake in the temporal, parietal, and
occipital lobes (temporal lobe: R = −0.530, P = 0.020; parietal
lobe: R = −0.637, P = 0.003; occipital lobe: R = −0.567, P = 0.011).
A similar pattern was observed for the frontal lobe, albeit without
reaching statistical significance (R = −0.421, P = 0.073) (Table 3).
Voxel-Wise PET Analyses
Compared to the NC group, the AD group had elevated [18F]-
APN-1607 binding in fusiform gyrus (BA 37), superior temporal
gyrus (BA 21), inferior temporal gyrus (BA 20), middle frontal
gyrus (BA 8, 9, 11), and cingulate gyrus (BA 32) at FWE P < 0.01
(Table 4 and Figure 3).
Significantly negative correlations between MMSE and brain
[18F]-APN-1607 binding were found mainly in superior frontal
gyrus (BA 10), middle frontal gyrus (BA 9, 10, 11, 47),
parahippocampal gyrus (BA 36) and lateral globus pallidus at
P < 0.01 (uncorrected). Of these, both the superior frontal gyrus
(BA 10) and middle frontal gyrus (BA 9, 10) survived FWE at
P < 0.05 (Table 5 and Figure 4).
DISCUSSION
In this present study, we characterized the [18F]-APN-1607
uptake pattern in patients with AD in comparison with NC
subjects. Furthermore, we assessed the correlation with between
tau PET with [18F]-FDG PET and clinical parameters (MMSE).
Our main objective was to characterize the utility of this next-
generation tau tracer in terms of effect size for detecting disease-
specific tau deposition, thus confirming the known relationship
between tau deposition and decreased FDG uptake and cognitive
impairment in AD patients.
In the regional analysis of [18F]-APN-1607, we found AD
patients had higher binding than NC subjects in widespread
regions of the cerebral cortex, caudate, and putamen and
conversely relatively low uptake in the brainstem. The voxel-
wise analysis results were in agreement with those of the
region-based analysis, and the cerebral regions with increased
tau deposition to [18F]-APN-1607 were consistent with
previously published studies for previous-generation tau
tracers (Table 6).
Hitherto, only limited data for second-generation tau tracers
have been reported (Leuzy et al., 2019). Some novel tau tracers
generally presented a number of advantages over the previous
generation, notably with respect to target selectivity. For example,
in vitro studies suggested that [18F]-MK6240 and [18F]-JNJ-067
bound with neurofibrillary tangle (NFT) (Hostetler et al., 2016),
whereas [18F]-RO948 bound to both NFT and neuropil threads
(Honer et al., 2018), whereas [18F]-JNJ64349311 interacted with
PHF-tau and neuropil threads (Declercq et al., 2017). [18F]-
PI2620 showed ambivalent binding to 3R-tau from PiD brain
and to 4R-tau from PSP samples (Kroth et al., 2019). [18F]-APN-
1607 showed specific binding with tau aggregates in AD and
PSP (Shimada et al., 2018). Furthermore, such tracers showed
improvement in off-target binding. [18F]-APN-1607 showed no
off-target binding in the basal ganglia and thalamus (Shimada
et al., 2017), and [18F]-APN-1607, [18F]-MK6240, [18F]-JNJ-607,
and [18F]-PI2620 revealed no off-target binding with MAO-A
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TABLE 1 | Demographic information and clinical characteristics.
Group No. Gender (male/female) Age of scanning (y) Age at onset (y) Education (y) MMSE score CDR-GS MTA-VRS
AD 19 7/12 61.8 ± 11.3 56.9 ± 10.5 10.7 ± 4.2 17.0 ± 7.6 1 (1–2) 2 (2–2)
NC 11 7/4 61.8 ± 4.6 – N.A. N.A. 0 (0–0) 1 (0–1)
P – 0.156a 0.992b – – – <0.001c <0.001c
For age, education years, and MMSE score; the expression means mean ± standard deviation. For CDR-GS and MTA-VRS, the expression means median (interquartile
range). aχ2 test was performed. b Independent two-tailed Student t test was performed. cMann-Whitney U test was performed. AD, Alzheimer’s disease; NC, normal
control; MMSE, Mini-Mental State Examination; CDR-GS, Clinical Dementia Rating Global Score; MTA-VRS, Medial Temporal Lobe Atrophy Visual Rating Scale; N.A., not
available; y, year.
FIGURE 1 | Representative examples of [18F]-APN-1607 PET and anatomical MRI superimposed images of AD and NC subjects. (A) [18F]-APN-1607 PET of an AD
patient (male, 56 years old, MMSE 17, 11 years’ education experience, memory impairment complaint for 5 years with positive [11C]-PiB result). (B) [18F]-APN-1607
PET of a NC subject (Male, 61y). AD, Alzheimer’s disease; NC, normal control. The color stripe indicates the standard uptake value ratio with cerebellar cortex as the
reference region.
TABLE 2 | Differences of [18F]-APN-1607 regional SUVR between AD and
NC groups.
VOI SUVR P Cohen d
AD NC
Frontal lobe 1.43 ± 0.42 0.85 ± 0.06 <0.001*** 1.926
Temporal lobe 1.64 ± 0.50 0.91 ± 0.06 <0.001*** 2.062
Occipital lobe 1.58 ± 0.47 0.95 ± 0.06 <0.001*** 1.917
Parietal lobe 1.62 ± 0.60 0.87 ± 0.06 <0.001*** 1.773
Insula 1.31 ± 0.41 0.85 ± 0.07 <0.001*** 1.546
Cingulum 1.47 ± 0.46 0.89 ± 0.05 <0.001*** 1.801
Caudate 0.91 ± 0.17 0.80 ± 0.04 0.015* 0.898
Putamen 1.18 ± 0.22 0.94 ± 0.05 <0.001*** 1.508
Pallidum 1.11 ± 0.19 1.05 ± 0.08 0.295 0.376
Thalamus 1.21 ± 0.23 1.27 ± 0.12 0.374 0.325
Midbrain 0.91 ± 0.17 1.04 ± 0.05 0.008** 1.005
Pons 0.85 ± 0.17 1.03 ± 0.06 <0.001*** 1.397
Medulla 0.72 ± 0.18 0.95 ± 0.11 <0.001*** 1.537
For SUVR, the expression means mean ± standard deviation. VOI, volume of
interest; SUVR, standard uptake value ratio; AD, Alzheimer’s disease; NC, normal
control. *P < 0.05, **P < 0.01, ***P < 0.001.
and MAO-B. Extensive screening of [18F]-RO948 also revealed
no off-target binding. These limited available data suggested
that novel-generation tau tracers had significant advantages in
FIGURE 2 | Differences of regional [18F]-APN-1607 SUVR between AD and
NC groups. AD, Alzheimer’s disease; NC, normal control. *P < 0.05,
**P < 0.01, ***P < 0.001.
comparison to previous generation tracers. The selectivity for
tau isoforms of the different series renders them particularly
suitable for the investigation of neurodegenerative disease
apparent. Further clinical studies are required to demonstrate
their diagnostic utility and to further evaluate their performance.
The limited in vivo data reported for other new-generation
tau tracers showed similar results to our study: [18F]-MK6240,
[18F]RO-948, and [18F]-PI6260 showed elevated signals in
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TABLE 3 | Correlations between regional SUVR and MMSE score, and correlations between multimodes in AD group.
VOI 18F-APN-1607 and MMSE 18F-FDG and MMSE 18F-APN-1607 and 18F-FDG
P R P R P R
Frontal lobe 0.004** −0.632 0.043* 0.469 0.073 −0.421
Temporal lobe 0.008** −0.593 0.057 0.444 0.020* −0.530
Occipital lobe 0.076 −0.417 0.341 0.231 0.011* −0.567
Parietal lobe 0.014* −0.552 0.015* 0.550 0.003** −0.637
Insula 0.003** −0.650 0.411 0.200 0.616 −0.123
Cingulum 0.002** −0.665 0.630 0.118 0.333 −0.235
Caudate 0.067 −0.429 0.780 −0.069 0.091 0.398
Putamen 0.013* −0.557 0.693 −0.097 0.251 0.277
Pallidum 0.395 −0.207 0.102 −0.387 0.743 0.081
Thalamus 0.007** −0.595 0.912 0.027 0.808 −0.060
Midbrain 0.531 −0.153 0.150 −0.343 0.892 −0.033
Pons 0.301 −0.250 0.461 −0.180 0.399 −0.205
Medulla 0.043* −0.469 0.080 −0.411 0.705 0.093
VOI, volume of interest; R, Spearman correlation. *P < 0.05, **P < 0.01, ***P < 0.001.
TABLE 4 | Brain regions with significant increased uptakes of [18F]-APN-1607 in AD group compared to NC Group (P < 0.01, FWE corrected).
Region* Hemisphere Cluster size (mm3) Z max Coordinates†
X Y Z
Fusiform gyrus (BA 37) Left 283,064 5.72 −48 −44 −18
Superior temporal gyrus (BA 21) Right 283,064 5.53 62 −22 −4
Inferior temporal gyrus (BA 20) Left 283,064 5.50 −54 −24 −22
Middle frontal gyrus (BA 8) Right 56,784 5.17 22 38 34
Middle frontal gyrus (BA 8) Right 56,784 5.17 30 30 34
Middle frontal gyrus (BA 9) Right 56,784 5.13 10 48 18
Middle frontal gyrus (BA 8) Left 51,360 5.06 −10 38 34
Middle frontal gyrus (BA 11) Left 51,360 5.05 −26 48 −14
Cingulate gyrus (BA 12) Left 51,360 5.03 −10 26 42
*Significant at FWE-corrected voxel threshold of P < 0.01, extent threshold = 58 voxels (464 mm3). †Coordinates are displayed in MNI standard space. BA, Brodmann
area; FWE, familywise error.
temporal areas and more broadly throughout the cortex in AD
patients compared to NC subjects. The SUVRs in temporal
lobe of AD/MCI patients were 1.64 (±0.72) with [18F]-MK6240
[MMSE = 18.8 (±6.9), Cohen d = 1.3) (Lohith et al., 2019), 2.75
(±1.40) with [18F]RO-948 (inferior temporal lobe, MMSE = 20.8
(±2.7), Cohen d = 1.6] (Wong et al., 2018), and 1.80 (±0.40) with
[18F]-PI2620 [inferior temporal, MMSE = 20.4 (±6.3), Cohen
d = 2.4] (Mueller et al., 2019). Our findings of [18F]-APN-1607
had relatively lower SUVR in the present study [temporal lobe:
1.64 (±0.50), MMSE = 17.0 (±7.6), Cohen d = 2.1] comparing
to [18F]RO-948 and [18F]-PI2620, which might arise from the
relatively rough ROI; however, the relatively high Cohen d value
indicated that [18F]-APN-1607 was a highly sensitive tracer for
detecting tau aggregates in AD. Findings in other brain regions
were also comparable among the next-generation tau tracers,
including [18F]-APN-1607 (Table 6).
In addition to the finding of distinctly elevated [18F]-APN-
1607 binding in the widespread cerebral cortex of patients
with AD of moderate severity, we also saw increased signals
in the striatum. We noted that [18F]-AV-1451, [18F]-RO948,
and [18F]-PI2620 likewise showed similarly increased signals
in the striatum (Shcherbinin et al., 2016; Wong et al., 2018;
Mueller et al., 2019). Previous neuropathological observation
addressed that NFT occurs in striatum in late Braak stages of
AD (V and VI) (Chan and Shea, 2006). Another autopsied
study reinforced AD cases with severe putaminal tauopathy
at the advanced stages and indicated that severe microtubule-
associated protein tau accumulation in the basal ganglia might
occur most frequently in AD cases, without comorbidity of
other neurodegenerative diseases in a general aging population
(Hamasaki et al., 2019). Accordingly, the higher [18F]-APN-1607
PET signal seen in caudate and putamen of our AD group
might suggest higher than expected tauopathy (Su et al., 2015).
Nonetheless, previous MRI studies reported iron overloading in
striatum in AD (Bartzokis et al., 1993, 1994; Acosta-Cabronero
et al., 2013). Iron is a known component of neuritic plaques
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FIGURE 3 | Voxel-wise differences of whole-brain [18F]-APN-1607 binding in the AD group compared to the NC Group. AD, Alzheimer’s disease; NC, normal
control. Increased binding is displayed in red; decreased binding is displayed in blue. The color stripe indicates the t value; voxel threshold P < 0.01, FWE-corrected.
T statistic maps are displayed in MNI standard space.
TABLE 5 | Brain regions exhibiting a significant negative correlation between MMSE score and regional brain uptakes of [18F]-APN-1607 in AD group
(P < 0.01, uncorrected).
Region* Hemisphere Cluster size (mm3) Z Max Coordinates†
X Y Z
Superior frontal gyrus (BA 10)‡ Right 91,784 3.65 16 60 −16
Middle frontal gyrus (BA 10)‡ Right 91,784 3.43 36 52 −16
Middle frontal gyrus (BA 9)‡ Right 91,784 3.24 38 36 28
Middle temporal gyrus (BA 21) Right 19,376 3.00 68 −28 −10
Parahippocampal gyrus (BA 36) Right 19,376 2.95 34 −34 −12
Lentiform nucleus (lateral globus pallidus) Right 19,376 2.89 28 −12 −12
Middle frontal gyrus (BA 10) Left 20,664 2.98 −30 54 −16
Middle frontal gyrus (BA 47) Left 20,664 2.90 −46 38 −10
Middle frontal gyrus (BA 11) Left 20,664 2.87 −26 34 −20
*Significant at uncorrected voxel threshold of P < 0.01, extent threshold = 937 voxels (7,504 mm3). †Coordinates are displayed in MNI standard space. ‡Survived at
FWE-corrected voxel threshold of P < 0.05. BA, Brodmann area; FWE, familywise error.
FIGURE 4 | Voxel-wise correlation of MMSE score and whole-brain [18F]-APN-1607 binding in the AD group. AD, Alzheimer’s disease; NC, normal control. Positive
correlations are displayed in red; negative correlations are displayed in blue. The color stripe indicates the t value; voxel threshold P < 0.01, uncorrected. Images are
displayed in MNI standard space.
(Grundke-Iqbal et al., 1990; Connor et al., 1992; LeVine,
1997; Lovell et al., 1998) and neurofibrillary tangles (Good
et al., 1992), and the Fenton reaction has long been suspected
to contribute to AD pathology (Smith et al., 1997). Indeed,
excessive ferrous iron may well favor β-amyloid aggregation and
otherwise produce neurotoxicity (Schubert and Chevion, 1995;
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TABLE 6 | Summary of ROI analyses of different tau tracers in AD and NC groups.
Cohorts NC AD Cohen d
[18F]-AV-1451 (Shcherbinin et al., 2016) AD N = 5, MMSE = 21.8 (4.1) NC N = 5,
MMSE = MMSE = 29.6 (0.5)
Frontal 1.00 (0.16) 1.65 (0.69) 1.30
Occipital 1.07 (0.18) 1.67 (0.59) 1.38
Lateral parietal 1.05 (0.19) 2.03 (0.84) 1.61
Mesial temporal 1.09 (0.14) 1.78 (0.48) 1.95
Lateral temporal 1.10 (0.15) 2.15 (0.89) 1.65
Putamen 1.34 (0.09) 1.78 (0.23) 2.52
[18F]-THK5351 (Kang et al., 2017) AD N = 51, MMSE = 13.8 (6.0) NC N = 43,
MMSE = 28.5 (1.6)
Frontal 1.35 (0.22) 2.05 (0.34) 2.44
Occipital 1.09 (0.15) 1.57 (0.46) 1.40
Superior parietal 1.18 (0.20) 1.80 (0.43) 1.85
Inferior parietal 1.34 (0.21) 2.60 (0.69) 2.47
Lateral temporal 1.60 (0.23) 2.71 (0.49) 2.90
Mesial temporal 2.42 (0.27) 3.52 (0.59) 2.40
Anterior cingulate 2.88 (0.43) 3.40 (0.57) 1.03
Hippocampus 2.44 (0.27) 3.40 (0.55) 2.22
Fusiform 1.51 (0.19) 2.39 (0.57) 2.07
Entorhinal 2.15 (0.34) 3.36 (0.89) 1.80
Basal ganglia 3.08 (0.48) 3.72 (0.62) 1.15
[11C]-PBB3 (Kitamura et al., 2018) AD/MCI N = 7, MMSE = 23.7 (6.9) NC N = 9,
MMSE = 29.4 (0.7)
Frontal 0.86 (0.04) 0.94 (0.09) 1.15
Occipital 0.90 (0.03) 1.05 (0.07) 2.79
Parietal 0.83 (0.05) 0.97 (0.09) 1.92
Medial temporal 0.99 (0.05) 1.02 (0.05) 0.60
Lateral temporal 0.95 (0.04) 1.05 (0.06) 1.96
Anterior cingulate 0.91 (0.07) 0.94 (0.01) 0.60
[18F]-MK6240 (Lohith et al., 2019) AD N = 4, MMSE = 16.5 (7.3) NC N = 4,
MMSE = 29.0 (0.0)
Temporal 0.98 (0.07) 1.64 (0.72) 1.29
Hippocampus 0.93 (0.10) 1.37 (0.25) 2.31
Amygdala 0.84 (0.11) 1.67 (0.40) 2.83
Caudate 0.79 (0.06) 0.71 (0.16) 0.66
Putamen 0.91 (0.04) 1.15 (0.35) 0.96
[18F]-RO948 (Wong et al., 2018) AD N = 11, MMSE = 20.8 (2.7) NC N = 5) Middle frontal lobe 1.13 (0.10) 2.27 (1.40) 1.15
Lateral occipital lobe 1.35 (0.10) 2.34 (1.30) 1.07
Precuneus 1.16 (0.20) 2.29 (1.50) 1.06
Superior parietal 1.24 (0.10) 2.18 (1.10) 1.20
Inferior parietal 1.32 (0.10) 2.8 (1.50) 1.39
Inferior temporal 1.14 (0.10) 2.75 (1.40) 1.62
Middle temporal 1.15 (0.10) 2.54 (1.40) 1.40
Posterior cingulate 1.1 (0.10) 1.96 (1.20) 1.01
Insula 0.98 (0.10) 1.46 (0.50) 1.33
Hippocampus 0.90 (0.20) 1.26 (0.30) 1.40
Parahippocampus 0.96 (0.10) 1.95 (0.70) 1.97
Amygdala 0.81 (0.10) 1.72 (0.70) 1.83
Caudate 0.80 (0.10) 0.97 (0.20) 1.06
Putamen 0.93 (0.10) 1.28 (0.20) 2.24
Thalamus 0.90 (0.10) 1.00 (0.20) 0.69
[18F]-PI2620 (Mueller et al., 2019) AD N = 12, MMSE = 20.4 (6.3) NC N = 10,
MMSE = 29.0 (1.2)
Occipital 1.08 (0.08) 1.45 (0.23) 2.15
Parietal 1.03 (0.06) 1.53 (0.40) 1.75
Superior temporal 1.07 (0.10) 1.36 (0.23) 1.64
Inferior temporal 1.09 (0.10) 1.80 (0.40) 2.44
Posterior cingulate 1.03 (0.13) 1.82 (0.68) 1.61
(Continued)
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TABLE 6 | Continued
Cohorts NC AD Cohen d
Hippocampus 1.07 (0.08) 1.26 (0.20) 1.25
Parahippocampus 1.07 (0.11) 1.46 (0.29) 1.78
Amygdala 0.99 (0.11) 1.29 (0.29) 1.37
Fusiform 1.07 (0.11) 1.63 (0.29) 2.55
Striatum 0.83 (0.1) 1.02 (0.14) 1.56
Pallidum 0.95 (0.17) 1.10 (0.14) 0.96
Thalamus 0.93 (0.11) 0.96 (0.07) 0.33
AD, Alzheimer’s disease; NC, normal control.
Leskovjan et al., 2011). Furthermore, iron can induce
hyperphosphorylation and aggregation of tau (Lovell et al.,
2004; Chan and Shea, 2006). Altogether, we interpreted these
findings with much caution, given that previous generation tau
tracers such as [18F]-AV-1451 demonstrated off-target binding
to ferrous iron (Lowe et al., 2016; Passamonti et al., 2017;
Choi et al., 2018; Baker et al., 2019), which as described above
was implicated in the neuropathology of neurofibrillary tangle
formation. Noteworthy, [18F]-AV-1451 has shown non-specific
binding in the striatum in healthy elderly subjects (Marquie
et al., 2015; Passamonti et al., 2017; Smith et al., 2017), and its
binding appeared to increase with healthy aging (Smith et al.,
2017). Similarly, the first-generation [11C]-PBB3 also showed
off-target binding in the basal ganglia, the reason for which was
yet to be determined (Ono et al., 2017), although a recent abstract
indicated there was no off-target binding in the basal ganglia and
thalamus for [18F]-APN-1607 (Shimada et al., 2017).
In this study, we investigated clinical correlations for [18F]-
APN-1607 and [18F]-FDG uptakes separately. The MMSE score,
as a surrogate for general cognition, showed strong correlations
with [18F]-APN-1607 SUVR in all cerebral cortical regions except
the occipital lobe, and with [18F]-FDG SUVR in the frontal and
parietal lobes (Table 3). In [18F]-APN-1607, we also saw relatively
weaker correlations in the putamen, thalamus, and medulla.
It was hypothesized that accumulation of toxic intracellular
aggregate accompanied by a loss of soluble tau capable
of stabilizing microtubules might synergistically lead to
compromised neuronal survival (Lee et al., 2011), accounting
for the putative relationship between NFT burden and cognitive
decline in AD patients (Terry et al., 1981; Gomez-Isla et al.,
1997). According to the Braak theory of AD propagation
(Braak and Braak, 1991b; Braak and Del Tredici, 2011), tau
deposition spreads widely and aggregates in neocortical areas
in advanced AD patients. The association we observed between
tau depositions to [18F]-PAPN-1607 and general cognitive
impairment was consistent with these known relationships,
which we could now confirm here with a new-generation tau
tracer. The occipital lobe was thought to be affected at only a
late stage of typical AD progression (Delacourte et al., 1999)
and likewise showed tau accumulation only at a late stage
(Alafuzoff et al., 2008). In this regard, our study’s failure to show
a correlation between tau deposition and [18F]-APN-1607 in
the occipital lobe, and MMSE score was consistent with the
moderate severity of disease in our patient group.
We found a negative correlation between tau deposition
to [18F]-APN-1607 in some subcortical regions and MMSE
score. Degeneration of deep gray matter structures other than
the hippocampus and the amygdala occurred in the process
of AD and ultimately contributes to cognitive deterioration.
The thalamus pathology played an increasingly recognized role
in early memory loss of AD patients (Aggleton and Brown,
1999; Harding et al., 2000; Taber et al., 2004; Carlesimo et al.,
2011). The anterodorsal thalamic nucleus was posited to undergo
neurofibrillary changes concomitant with the hippocampus
(Braak Stages III–IV) (Braak and Braak, 1991b). Nonetheless,
some thalamic nuclei appeared unaffected or show only mild
neurofibrillary changes, even in cases of severe AD (Braak
and Braak, 1991b). Recent studies have provided evidence that
AD-related tau cytoskeletal pathology is initiated in subcortical
regions, which supports the widely held hypothesis that early
occurring subcortical tau cytoskeletal pathology, including that
in the thalamus, may play a crucial role in the cascade of the
early pathological events of AD (Rub et al., 2000; Grinberg
et al., 2009; Stratmann et al., 2016). In addition, the clinical
manifestation and progression of AD correlated with loss
of neurons, synaptic degeneration in the neocortex and the
topographical distribution of the tau cytoskeletal pathology in
diseased brains (Jack et al., 2016). The role of the cortical and
subcortical regions of the limbic system in the performance of
normal cognitive and memory functions was well-known. The
presence of severe tau cytoskeletal pathology in the thalamic
nuclei with limbic connectivity likely contributed to impaired
neural processing in limbic circuits, manifesting in certain
cardinal symptoms of AD (Braak and Braak, 1991a,b; Rub et al.,
2000, 2002; Blennow et al., 2006; Lace et al., 2007; Grinberg
et al., 2009; Braak and Del Trecidi, 2015). Structural MRI
studies also showed that overall thalamic volume correlates
with cognitive status in MCI and AD patients (de Jong et al.,
2008; Pedro et al., 2012; Yi et al., 2016), further highlighting
its role in the pathogenesis of AD. In this regard, the negative
correlation between [18F]-APN-1607 binding in the thalamus
and MMSE score in the AD group offered further support,
a link between thalamic pathology and cognitive impairment.
Like thalamus, the basal nuclei participated in many different
neuronal pathways, with functions extending to emotional,
motivational, associative, and cognitive processes (Herrero
et al., 2002). A previous MRI study has found significantly
reduced putamen volumes in AD patients, correlating with
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impaired cognition (de Jong et al., 2008). Combined with the
neuropathological observation that NFT occurs in striatum in
Braak stages V and VI in AD (Chan and Shea, 2006), our findings
strongly suggested that the tau deposition in the subcortical
regions may also contribute to cognitive decline in AD.
Cerebral [18F]-FDG uptake provides a surrogate marker for
neuronal metabolism. [18F]-FDG uptake in the frontal (R = 0.469,
P = 0.043) and parietal lobes (R = 0.550, P = 0.015) correlated with
MMSE score of our AD group, with weaker association for the
temporal lobe (R = 0.444, P = 0.057). Numerous PET studies have
demonstrated hypometabolism in the temporoparietal cortex of
AD patients (Minoshima et al., 1995; Kato et al., 2016; Rice and
Bisdas, 2017), whereas hypometabolism in the frontal lobe is
often observed during the progression of AD dementia (Herholz
et al., 2007). Thus, our present findings of regional correlation
were concordant with the known hypometabolic regions in AD.
The relatively weak correlation in the temporal lobe could be
indicative of involvement at an early stage of neurodegeneration,
with stabilization of the hypometabolism late in this disease,
resulting in a weakening of the relationship between temporal
hypometabolism with cognitive scores. Indeed, previous [18F]-
FDG PET studies have suggested that temporal hypometabolism
peaks at the MCI stage and does not progress at later stages of
the disease (Dukart et al., 2013), which seems consistent with
present findings.
Our multimodal analysis revealed several brain regions
showing correlations between uptake of both tracers. Previous
studies posited that cognitive deficits in AD could arise
directly from both tau pathology and subsequent downstream
neurodegeneration (Bejanin et al., 2017). We found that SUVRs
in the temporal (R = −0.530, P = 0.020), parietal (R = −0.637,
P = 0.003), and occipital (R = −0.567, P = 0.011) lobes
correlated negatively between [18F]-APN-1607 and [18F]-FDG
uptakes, with a trend toward negative correlation in the
frontal lobe (P = 0.073, R = −0.421). These findings were
consistent with results disclosed using other tau tracers [[18F]-
AV-1451 (Gordon et al., 2019; Sintini et al., 2019) and [18F]-
THK5351 (Baghel et al., 2019)]. Previous stereological and
non-stereological quantitative post-mortem studies of cerebral
cortex (Terry et al., 1981, 1987; Cras et al., 1995; Schwab
et al., 1998, 1999; Bussiere et al., 2002; Kril et al., 2002) and
clinicopathologic studies (Giannakopoulos et al., 2003) reported
a close association between NFT counts and neuron loss.
However, non–NFT-related mechanisms of neurodegeneration
may also play a role in the loss of cortical neurons in AD
(Gomez-Isla et al., 1997).
In summary, this preliminary clinical study confirmed the
utility of the new compound [18F]-APN-1607 for the detection of
tau pathology and reinforced previous studies showing an overlap
between cerebral glucose hypometabolism (using [18F]-FDG
PET) and tau deposition and their association with dementia.
Limitations
We noted several shortcomings in this study. First, our group
size in this preliminary study was relatively small. Second,
to reduce the radiation exposure to the NC group, we did
not perform additional β-amyloid or [18F]-FDG PET scanning
to conform lack of pathology. However, clinical and MRI
assessment revealed normal results. Although the abnormal
metabolic regions of AD patients are well-described from a
plethora of previous publications, we lacked [18F]-FDG PET data
for the NC group. In mitigation, we restricted our exploration
in the AD group with region-to-region analysis, aiming to
explore anatomic relationships between tau deposition and
abnormal metabolism. We draw attention to the fact that
MMSE reflected only general cognition, whereas individuals
may suffer from cognitive impairment in different domains.
Future studies involving more detailed cognitive assessments
would support a better exploration of the relationships between
tauopathy and cognition.
We were cognizant of the methodological challenges
associated with choice of reference region. We used cerebellum,
a commonly chosen region, for normalization of [18F]-APN-
1607 and [18F]-FDG scans to SUVR maps. Validity of this
approach naturally required absence of important pathologies
in cerebellum. In future studies, we shall consider other
possible methods of normalization. Finally, clinical studies of
prospective design are required to further validate the promising
results reported here.
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